Dr. Reddys Lab receives approval for de-addiction film

Dr. Reddy's Laboratories has received final approval from the US drug regulator for launching Buprenorphine and Naloxone Sublingual Film in the US market. The product is being launched through an approved Risk Evaluation and Mitigation Strategy (REMS) Program.

The medication is a generic version of Suboxone sublingual film. The company's Buprenorphine and Naloxone Sublingual Film 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg was approved by the US Food and Drug Administration (USFDA).

Buprenorphine and naloxone are prescribed to adults with opioid dependence/addiction. Buprenorphine helps suppress withdrawal symptoms caused by discontinuation of opioid drugs, and naloxone reverses and blocks the effect of opioids. This combination of medications is used as part of a complete treatment program including prescription monitoring and counseling support.

Dr Reddy's Laboratories has been catering to the needs of the pharmaceutical sector for over two decades. Active Pharmaceutical Ingredients (API) segment with a diversified portfolio is the company's core strength.

Meanwhile, the stock on Friday opened at Rs. 2,319 per share and touched a high of Rs. 2,364.70 and a low of Rs. 2290. At 12:11 hours, the stock is quoting at Rs. 2372.00 which is up by 4.57 per cent.